Nurix Therapeutics Posts $673.1 Million Q3 Revenue on Major Roche Deal
Nurix Therapeutics, Inc. (NRIX) reported Q3 2026 revenue of $673.1 million, up from $7.9 million in the prior-year period. Net income reached $549.8 million for the quarter. The sharp increase was driven primarily by $653.2 million in licensing revenue tied to a collaboration with Roche, which included a $700 million upfront payment.
The licensing revenue significantly strengthens the balance sheet, bringing total cash and securities to $1.1 billion. This extends the company operating runway into the second half of 2029 and reduces near-term financing risks. Additionally, Nurix earned a $10.0 million milestone payment from Sanofi, further validating its partnered pipeline.
Looking ahead, investors will focus on progress in the clinical pipeline, including the late-stage Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg against pirtobrutinib. Key value catalysts will depend on Phase 3 safety and efficacy readouts, as well as revenue clarity beyond finite licensing fees.
Key points
- Nurix Therapeutics reported third-quarter 2026 revenue of $673.1 million, compared to $7.9 million in the prior year.
- Net income for the quarter reached $549.8 million, driven by $653.2 million in licensing revenue from Roche.
- Cash and securities reached $1.1 billion following a $700 million upfront payment, extending the cash runway into H2 2029.
- The company started the Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg against pirtobrutinib.
- Nurix earned a $10.0 million milestone payment from Sanofi.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were Nurix Therapeutics Q3 2026 financial results?
Nurix Therapeutics reported Q3 2026 revenue of $673.1 million and net income of $549.8 million. Revenue surged from $7.9 million in the year-ago period, primarily driven by $653.2 million in licensing revenue from a collaboration with Roche.
How much cash does Nurix Therapeutics have?
Nurix Therapeutics holds $1.1 billion in cash and securities following a $700 million upfront payment from Roche. This cash position extends the company runway into the second half of 2029.
What is the next clinical milestone for Nurix Therapeutics?
Nurix has started the Phase 3 DAYBreak CLL-306 trial to evaluate bexobrutideg against pirtobrutinib. Key value drivers will depend on upcoming Phase 3 efficacy and safety readouts.